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Background: Limb malformations are rare disorders with high genetic heterogeneity. Although multiple genes/loci
have been identified in limb malformations, underlying genetic factors still remain to be determined in most
patients.
Methods: This study consisted of 51 Japanese families with split-hand/foot malformation (SHFM), SHFM with long
bone deficiency (SHFLD) usually affecting the tibia, or Gollop-Wolfgang complex (GWC) characterized by SHFM and
femoral bifurcation. Genetic studies included genomewide array comparative genomic hybridization and exome
sequencing, together with standard molecular analyses.
Results: We identified duplications/triplications of a 210,050 bp segment containing BHLHA9 in 29 SHFM patients,
11 SHFLD patients, two GWC patients, and 22 clinically normal relatives from 27 of the 51 families examined, as well
as in 2 of 1,000 Japanese controls. Families with SHFLD- and/or GWC-positive patients were more frequent in
triplications than in duplications. The fusion point was identical in all the duplications/triplications and was
associated with a 4 bp microhomology. There was no sequence homology around the two breakpoints,
whereas rearrangement-associated motifs were abundant around one breakpoint. The rs3951819-D17S1174
haplotype patterns were variable on the duplicated/triplicated segments. No discernible genetic alteration specific to
patients was detected within or around BHLHA9, in the known causative SHFM genes, or in the exome.
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Conclusions: These results indicate that BHLHA9 overdosage constitutes the most frequent susceptibility factor, with a
dosage effect, for a range of limb malformations at least in Japan. Notably, this is the first study revealing the
underlying genetic factor for the development of GWC, and demonstrating the presence of triplications involving
BHLHA9. It is inferred that a Japanese founder duplication was generated through a replication-based mechanism and
underwent subsequent triplication and haplotype modification through recombination-based mechanisms, and that
the duplications/triplications with various haplotypes were widely spread in Japan primarily via clinically normal carriers
and identified via manifesting patients. Furthermore, genotype-phenotype analyses of patients reported in this study
and the previous studies imply that clinical variability is ascribed to multiple factors including the size of duplications/
triplications as a critical factor.
Keywords: BHLHA9, Split-hand/foot malformation, Long bone deficiency, Gollop-Wolfgang complex, Expressivity,
Penetrance, Susceptibility, Japanese founder copy number gainIntroduction
Split-hand/foot malformation (SHFM), also known as
ectrodactyly, is a rare limb malformation involving the
central rays of the autopod [1,2]. It presents with median
clefts of the hands and feet, aplasia/hypoplasia of the
phalanges, metacarpals, and metatarsals, and syndactyly.
SHFM results from failure to maintain the central por-
tion of the apical ectodermal ridge (AER) in the develop-
ing autopod [1,2]. SHFM is divided into two forms: a
non-syndromic form with limb-confined manifestations
and a syndromic form with extra-limb manifestations [2].
Furthermore, non-syndromic SHFM can occur as an
isolated abnormality confined to digits (hereafter, SHFM
refers to this type) or in association with other limb abnor-
malities as observed in SHFM with long bone deficiency
(SHFLD) usually affecting the tibia and in Gollop-Wolfgang
complex (GWC) characterized by femoral bifurcation [1,2].
Both syndromic and non-syndromic forms are associated
with wide expressivity and penetrance even among
members of a single family and among limbs of a sin-
gle patient [2].
SHFM and SHFLD are genetically heterogeneous condi-
tions reviewed in ref. [2]. To date, SHFM has been identified
in patients with heterozygous deletions or translocations in-
volving the DLX5–DLX6 locus at 7q21.2–21.3 (SHFM1) [3]
(DLX5 mutations have been detected recently), heterozy-
gous duplications at 10q24 (SHFM3), heterozygous muta-
tions of TP63 at 3q27 (SHFM4), heterozygous deletions
affecting HOXD cluster at 2q31 (SHFM5), and biallelic
mutations of WNT10B at 12q31 (SHFM6); in addition,
SHFM2 has been assigned to Xq26 by linkage analyses in
a large Pakistani kindred [2]. Similarly, a genomewide link-
age analysis in a large consanguineous family has identi-
fied two SHFLD susceptibility loci, one at 1q42.2–q43
(SHFLD1) and the other at 6q14.1 (SHFLD2); furthermore,
after assignment of another SHFLD locus to 17p13.1–13.3
[4], duplications at 17p13.3 (SHFLD3) have been found in
patients with SHFLD reviewed in ref. [2]. However, the
GWC locus (loci) remains unknown at present.The duplications at 17p13.3 identified to date are
highly variable in size, and harbor BHLHA9 as the sole
gene within the smallest region of overlap [5-9]. Bhlha9/
bhlha9 is expressed in the limb bud mesenchyme under-
lying the AER in mouse and zebrafish embryos, and
bhlha9 knockdown has resulted in shortening of the
pectoral fins in zebrafish [6]. Furthermore, BHLHA9-
containing duplications have been identified not only in
patients with SHFLD but also in those with SHFM and
clinically normal family members [4-10]. These findings
argue for a critical role of BHLHA9 duplication in the
development of SHFM and SHFLD, with variable ex-
pressivity and incomplete penetrance.
In this study, we report on BHLHA9-containing
duplications/triplications with an identical fusion point
and various haplotype patterns that were associated with
a range of limb malformations including GWC, and
discuss on characteristic clinical findings, genomic basis
of Japanese founder copy number gains, and underlying
factors for phenotypic variability.
Materials and methods
Patients/subjects
We studied 68 patients with SHFM (n = 55), SHFLD (n =
11), or GWC (n = 2), as well as 60 clinically normal rela-
tives, from 51 Japanese families; the pedigrees of 27 of the
51 families and representative clinical findings are shown
in Figure 1. All the probands 1–51 had a normal karyotype.
Southern blot analysis for SHFM3 locus had been per-
formed in 28 probands with SHFM, indicating 10q24 du-
plications in two of them [11]. Clinical features including
photographs and roentgenograms of a proband with GWC
and his brother with SHFLD (family 23 in Figure 1A)
were as described previously [12]. The residencies of
families 1–51 were widely distributed throughout Japan.
Ethical approval and samples
This study was approved by the Institutional Review
Board Committees of Hamamatsu University School of
Figure 1 Clinical summary. A. Pedigrees of 27 Japanese families with duplications (families 1–22) and triplications (families 23–27) of a ~200 kb
region involving BHLHA9. The duplications/triplications are associated with GWC, SHFLD, SHFM, or normal phenotype (carriers). N.E.: Not examined
molecularly. B. Representative clinical findings. Each patient is indicated by a family-generation-individual style and corresponds to the patient/
subject shown in Figure 1A and Additional file 5. The top panel: GWC with right bifid femur; the second panel: SHFLD with bilateral tibial deficiencies,
the third panel: SHFM with polydactyly; and the bottom panel: SHFM.
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and Development, and was performed using peripheral
leukocyte samples after obtaining written informed con-
sent for the molecular analysis and the publication of
genetic and clinical data after removing information for
personal identification (e.g., name, birthday, and facial
photograph) from the adult subjects (³ 20 years) or from
the parents of the child subjects (below 20 years). Fur-
thermore, informed assent was also obtained from child
subjects between 6–20 years.
Samples and primers
The primers utilized in this study are summarized in
Additional file 1.
Molecular studies
Sanger sequencing, fluorescence in situ hybridization
(FISH), microsatellite genotyping, Southern blotting, and bi-
sulfite sequencing-based methylation analysis were per-
formed by the standard methods, as reported previously
[13]. Quantitative real-time PCR (qPCR) analysis was carried
out by the SYBR Green methods on StepOnePlus system,
using RNaseP as an internal control (Life Technologies).
Genomewide oligonucleotide-based array comparative
genomic hybridization (CGH) was performed with a cata-
log human array (4 × 180 K format, ID G4449A) according
to the manufacturer’s instructions (Agilent Technologies),and obtained copy number variants/polymorphisms were
screened with Agilent Genomic Workbench software using
the Database of Genomic Variants (http://dgv.tcag.ca/dgv/
app/home). Sequencing of a long region encompassing
BHLHA9 was performed with the Nextera XT kit on
MiSeq (Illumina), using SAMtools v0.1.17 software (http://
samtools.sourceforge.net/). Exome sequencing was per-
formed as described previously [14].
Assessment of genomic environments around the fusion
points
Repeat elements around the fusion point were searched
for using Repeatmasker (http://www.repeatmasker.org).
Rearrangement-inducing DNA features were investigated
for 300 bp regions at both the proximal and the distal
sides of each breakpoint, using GEECEE (http://emboss.
bioinformatics.nl/cgi-bin/emboss/geecee) for calculation
of the average GC content, PALINDROME (http://mobyle.
pasteur.fr/cgi-bin/portal.py#forms::palindrome) and Non-B
DB (http://nonb.abcc.ncifcrf.gov) for the examination of
the palindromes and non-B (non-canonical) structures,
and Fuzznuc (http://emboss.bioinformatics.nl/cgi-bin/
emboss/fuzznuc) for the assessment of rearrangement-
associated sequence motifs and tri/tetranucleotides [15-20].
For controls, we examined 48 regions of 600 bp long
selected at an interval of 1.5 Mb from the entire
chromosome 17.
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The statistical significance of the frequency was analyzed
by the two-sided Fisher’s exact probability test.
Results
Sequence analysis of the known causative/candidate
genes
We performed direct sequencing for the previously known
causative genes (DLX5, TP63, and WNT10B) reviewed in
ref. [2] in the probands 1–51. Although no pathologic mu-
tation was identified in DLX5 and TP63, the previously
reported homozygous missense mutation of WNT10B
(c.944C > T, p.R332W) [21] was detected in the proband
48 with SHFM who was born to healthy consanguineous
parents heterozygous for this mutation. In addition,
while no variation was detected in DLX5 and WNT10B,
rs34201045 (4 bp insertion polymorphism) in TP63 [21]
was detected with an allele frequency of 61%.
We also examined BHLHA9, because gain-of-function
mutations of BHLHA9 as well as BHLHA9-harboring
duplications may lead to limb malformations. No se-
quence variation was identified in the 51 probands.
Array CGH analysis
Array CGH analysis was performed for the probands
1–51, showing increased copy numbers at 17p13.3
encompassing BHLHA9 (SHFLD3) in the probands 1–27
from families 1–27 (Figure 1A). Furthermore, heterozy-
gous duplications at 10q24 (SHFM3) were detected in the
probands 49–51, i.e., a hitherto unreported patient with
paternally inherited SHFM (his father also had the dupli-
cation) and the two patients who had been indicated to
have the duplications by Southern blot analysis [11]. No
copy number alteration was observed at other SHFM/
SHFLD loci in the probands 1–27 and 49–51. In the
remaining probands 28–48, there was no copy num-
ber variation that was not registered in the Database of
Genomic Variants.
Identical fusion points in BHLHA9-containing duplications/
triplications
The array CGH indicated that the increased copy num-
ber regions at 17p13.3 were quite similar in the physical
size in the probands 1–27 and present in three copies in
the probands 1–22 and in four copies in the probands
23–27 (Figure 2A). Thus, FISH analysis was performed
using 8,259 bp PCR products amplified from this region,
showing two signals with a different intensity that was
more obvious in the probands 23–27 (Figure 2A).
We next determined the fusion points of the duplica-
tions/triplications (Figure 2B). PCR products of 2,195 bp
long were obtained with P1/P2 primers in the probands
1–27, and the fusion point was determined by direct se-
quencing for 418 bp PCR products obtained with P3/P4primers. The fusion point was identical in all the probands
1–27; it resided on intron 1 of ABR and intron 1 of YWHAE,
and was associated with a 4 bp microhomology.
Then, we performed qPCR analysis for a 214 bp region
harboring the fusion point, using P5/P6 primers (Figure 2C
and Additional file 2). The fusion point was present in
a single copy in the probands 1–22 and in two copies
in the probands 23–27. The results showed that the
identical genomic segment harboring BHLHA9 was tan-
demly duplicated in the probands 1–22 and triplicated in
the probands 23–27. According to GRCh37/hg19 (http://
genome.ucsc.edu/), the genomic segment was 210,050 bp
long.
We also performed array CGH and qPCR for the fu-
sion point in 15 patients other than the probands and 47
clinically normal relatives from the 27 families (Figures 1
and 2C). The duplications/triplications were identified in
all the 15 patients. Thus, in a total of 42 patients, dupli-
cations/triplications were found in 29 SHFM patients, 11
SHFLD patients, and two GWC patients. Furthermore,
the duplications/triplications were also present in 22 of
the 47 clinically normal relatives. In particular, they were
invariably identified in either of the clinically normal
parents when both of them were examined; they were
also present in other clinically normal relatives in fam-
ilies 7, 12, 24, and 25.
Since the above data indicated the presence of duplications/
triplications in clinically normal subjects, we performed
qPCR for the fusion point in 1,000 Japanese controls. The
fusion point was detected in a single copy in two subjects
(Subjects 1 and 2 in Figure 2C). We also performed array
CGH in 200 of the 1,000 controls including the two sub-
jects, confirming the duplications in the two subjects and
lack of other copy number variations, including deletions
involving BHLHA9, which were not registered in the
Database of Genomic Variants in the 200 control subjects.
The frequency of duplications/triplications was signifi-
cantly higher in the probands than in the control subjects
(27/51 vs. 2/1,000, P = 3.5 × 10−37).
Various haplotype patterns on the duplicated/triplicated
segments
We carried out genotyping for rs3951819 (A/G SNP on
BHLHA9) and D17S1174 (CA repeat microsatellite locus)
on the genomic segment subjected to duplications/
triplications (Figure 2A), and determined rs3951819-
D17S1174 haplotype patterns. Representative results
are shown in Figure 2D, and all the data are available
on request. Various haplotype patterns were identified
on the single, the duplicated, and the triplicated seg-
ments, and the [A-14] haplotype was most prevalent on
the duplicated/triplicated segments (Table 1). While the
distribution of CA repeat lengths on the single segments
was discontinuous, similar discontinuous distribution was
Figure 2 (See legend on next page.)
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Table 1 The rs3951819 (A/G SNP) – D17S1174 (CA repeat
number) haplotype
Patterns of the 210,050 bp segment subjected to copy number gains
Haplotype pattern Family
<Single segment>
[A-14] 1, 5, 9, 15, 17, 19, 23, 26
[A-16] 12
[A-18] 3, 14, 15, 24, 25, 26




[G-14] 2, 3, 6, 12, 13, 19, 26
[G-18] 3, 5, 17, 18, 24, 25
[G-19] 9, 12, 18, 20, 25
[G-21] 1, 9, 19, 24, 27
[A-14] or [G-14] 16
[A-18] or [G-18] 4
[A-19] or [G-19] 4
[A-21] or [G-21] 16
<Duplicated segments>
[A-14] + [A-14] 5, 12, 13, 14, 15, 20
[A-14] + [A-18] 1
[A-14] + [G-18] or [G-14] + [A-18] 2, 3, 4, 6, 9, 16, 17
[A-14] + [G-18] or [A-14] + [G-19] 18
[A-14] + [G-14] or [G-14] + [G-14] 19
<Triplicated segments>
[A-14] + [A-14] + [A-14] 23, 24
[A-14] + [A-14] + [G-14] 25
[A-14] + [A-19] + [A-19] 26
[A-14] + [G-18] + [G-18] or [G-14] + [A-18] + [G-
18]
27
The haplotype patterns written in the left column have been detected in at least
one patient/subject in the families described in the right column.
Genotyping could not be performed in several patients/subjects who had been
repeatedly examined previously, because of the extremely small amount of DNA
samples that were virtually used up in the sequencing and array CGH analyses.
(See figure on previous page.)
Figure 2 Identification and characterization of the duplications/triplications involving BHLHA9 at chromosome 17p13.3. A. Array CGH
and FISH analyses in proband 1 and proband 23 with GWC. In array CGH analysis, the black and the red dots denote the normal and the increased
copy numbers, respectively. Since the log2 signal ratios for a ~200 kb region encompassing BHLHA9 are around +0.5 in the proband 1 and around
+1.0 in the proband 23, this indicates the presence of three and four copies of this region in the two probands, respectively. In FISH analysis, two red
signals with an apparently different density are detected by the 8,289 bp PCR probe (the stronger signals are indicated with asterisks). The green
signals derive from an internal control probe (CEP17). The arrows on the genes show transcriptional directions. Rs3951819 (A/G) resides within BHLHA9.
B. Determination of the fusion point. The fusion has occurred between intron 1 of ABR and intron 1 of YWHAE, and is associated with a 4 bp (GACA)
microhomology. P1–P4 show the position of primers. C. Quantitative real-time PCR analysis. The upper part denotes the fusion point. P5 & P6 show
the position of primers. The lower part shows the copy number of the fusion point in patients/subjects with duplications/triplications (indicated by a
family-generation-individual style corresponding to that in Figure 1 and Additional file 5). Subject-1 and subject-2 denote the two control subjects with
the duplication, and control-1 and control-2 represent normal subjects without the duplication/triplication. D. The rs3951819 (A/G SNP)–D17S1174
(CA repeat number) haplotype patterns in family 24. Assuming no recombination between rs3951819 and D17S1174, the haplotype patterns of the
family members are determined as shown here. The haplotype patterns of the remaining families have been interpreted similarly.
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Additional file 3).
Genomic environments around the breakpoints
The breakpoint on YWHAE intron 1 resided on a simple
Alu repeat sequence, and that on ABR intron 1 was
present on a non-repetitive sequence. There was no low
copy repeat around the breakpoints. Comparison of the
frequencies of known rearrangement-inducing DNA fea-
tures between 600 bp sequences around the breakpoints
and those of 48 regions selected at an interval of 1.5 Mb
from chromosome 17 revealed that palindromes, several
types of non-B DNA structures, and a rearrangement-
associated sequence motif were abundant around the
breakpoint on YWHAE intron 1 (see Additional file 4).
Clinical findings of families 1–27
Clinical assessment revealed several notable findings.
First, duplications/triplications were associated with
SHFM, SHFLD, GWC, or normal phenotype, with inter-
and intra-familial clinical variability (Figure 1A). Second,
in the 42 patients, split hand (SH) was more prevalent
than split foot (SF) (41/42 vs. 17/42, P = 6.2 × 10−9), and
long bone defect (LBD) was confined to lower extremities
(0/42 vs. 13/42, P = 4.1 × 10−5) (Table 2 and Additional
file 5). Third, there was no significant sex difference
in the ratio between patients with limb malformations and
patients/carriers with duplications/triplications (26/38
in males vs. 16/26 in females, P = 0.60) (Table 2 and
Additional file 5). Fourth, the ratio of LBD positive fam-
ilies was significantly higher in triplications than in dupli-
cations (4/5 vs. 16/22, P = 0.047) (Figure 1A and Table 2).
Fifth, while the duplications/triplications were transmitted
from patients to patients, from carriers to patients, and
from a carrier to a carrier (from I-1 to II-2 in family 12),
transmission from a patient to a carrier was not identified
(Figure 1A); it should be pointed out, however, that mo-
lecular analysis in a clinically normal child born to an af-
fected parent was possible only in a single adult subject
(II-1 in family 27), and that molecular analysis in clinically
Table 2 Summary of clinical findings in patients/carriers with duplications/triplications involving BHLHA9
SHFM (+) patients LBD (+) patients Patient ratio* LBD (+) families
SH SF P-value U-LBD L-LBD P-value Male Female P-value Trip Dup P-value
This study 41/42 17/42 6.2 × 10−9 0/42 13/42 4.1 × 10−5 26/38 16/26 0.60 4/5 16/22 0.047
Previous studies 63/84 23/84 8.6 × 10−10 11/91 42/91 5.7 × 10−7 68/114 31/79 5.7 × 10−3 … … …
Sum 104/126 40/126 1.1 × 10−16 11/133 55/133 3.0 × 10−10 94/152 47/105 7.6 × 10−3 … … …
SHFM: split-hand/foot malformation; SH: split hand; SF: split foot; LBD: long bone deficiency; U: upper; L: lower; Trip: triplication; and Dup: duplication.
In the previous studies, patients without detailed phenotypic description and those of unknown sex have been excluded (3–9).
*The ratio between patients with limb malformations and patients/carriers with duplications/triplications, i.e. the number of patients over the number of patients
plus carriers.
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subjects (II-2 in family 12 and II-1 in family 15). Lastly,
limb malformation was inherited in an apparently auto-
somal dominant manner (from patients to patients), or
took place as an apparently de novo event or as an appar-
ently autosomal recessive trait (from clinically normal par-
ents to a single or two affected children) (Figure 1A).
Attempts to identify a possible modifier(s)
The variable expressivity and incomplete penetrance in
families 1–27 suggest the presence of a possible modifier
(s) for the development of limb malformations. Thus, we
performed further molecular studies in patients/subjects
in whom DNA samples were still available, and com-
pared the molecular data between patients with SHFM
and those with SHFLD for the assessment of variable ex-
pressivity and between SHFM, SHFLD, or total patients
and carriers for the evaluation of incomplete penetrance.
We first examined the possibility that the modifier(s)
resides within or around BHLHA9 (see Additional file 6).
There was no BHLHA9 mutation in all the 21 examined
probands with SHFM, SHFLD, or GWC, as described in
the section of “Sequence analysis of the known causative/
candidate genes”. The rs3951819 A/G SNP pattern on the
duplicated/triplicated segments was apparently identical
between patients and carriers (e.g. Figure 2D), and the fre-
quency of A/G allele on the normal chromosome 17 was
similar between SHFM and SHFLD patients and be-
tween SHFM, SHFLD, or total patients and carriers
(see Additional file 7). The results of other known SNPs
on BHLHA9 (rs185242872, rs18936498, and rs140504068)
were not informative, because of absence or extreme rarity
of minor alleles. Furthermore, in SHFM families 7,
12, and 18, sequencing of a 7,406 bp region encompassing
BHLHA9 and Southern blot analysis using five probes and
MfeI-, SspI-, and SacI-digested genomic DNA revealed no
variation specific to the patients, and methylation analysis
for a CpG rich region at the upstream of BHLHA9 delin-
eated massive hypomethylation in all the patients/carriers
examined.
Next, we examined the possibility that a variant(s) of
known causative genes constitutes the modifier(s). Since
rs34201045 in TP63 was identified in the mutationanalysis, we compared rs34201045 genotyping data be-
tween the 27 probands and the 15 carriers. The allele
and genotype frequencies were similar between SHFM
and SHFLD patients and between SHFM, SHFLD, or
total patients and carriers (see Additional file 8).
We finally performed exome sequencing in SHFM fam-
ilies 13 and 17–19. However, there was no variation spe-
cific to the patients. In addition, re-examination of the
genomewide array CGH data showed no discernible copy
number variation specific to the patients.
Discussion
BHLHA9 overdosage and clinical characteristics
We identified duplications/triplications of a ~ 200 kb
genomic segment involving BHLHA9 at 17p13.3 in 27 of
51 families with SHFM, SHFLD, or GWC. To our know-
ledge, this is the first study revealing the underlying genetic
factor for the development of GWC, and demonstrating
the presence of triplications involving BHLHA9 that were
suggested but not confirmed in the previous studies [5,9].
Furthermore, this study indicates that BHLHA9-containing
duplications/triplications are the most frequent underlying
factor for the development of limb malformations at least
in Japan. Notably, SHFLD and GWC with LBD were sig-
nificantly more frequent in patients with triplications than
in those with duplications, and the duplications/triplica-
tions were identified in clinically normal familial members
and in the general population. These findings imply that
increased BHLHA9 copy number constitutes a strong
susceptibility, rather than a causative, factor with a dosage
effect for the development of a range of limb malforma-
tions. Since Bhlha9 is expressed in the developing ecto-
derm adjacent to the AER rather than the AER itself in
mouse embryos [6], BHLHA9 appears to play a critical
role in the limb development by interacting with the AER.
While the duplications/triplications identified in this study
included TUSC5 and generated an ABR-YWHAE chimeric
gene (Figure 2C), TUSC5 duplication and the chimeric
gene formation are not common findings in the previously
reported patients with duplications at 17p13.3 and SHFM
and/or SHFLD [5-9]. In addition, none of Tusc5, Abr,
and Ywhae is specifically expressed in the developing
mouse limb buds [22] (A Transcriptome Atlas Database
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eurexpress.org/ee/project/).
Several clinical findings are noteworthy in patients/
subjects with duplications/triplications. First, SH was
more frequent than SF in this study as well as in the previ-
ous studies, and LBD was confined to lower extremities in
this study and was more frequent in lower extremities
than in upper extremities in the previous studies (Table 2)
[4-10]. This implies that BHLHA9 overdosage exerts dif-
ferential effects on the different parts of limbs. Second,
while limb malformations were similarly identified be-
tween males and females in this study, they were more fre-
quently observed in males than in females in the previous
studies (Table 2) [4-10]. In this regard, it has been re-
ported that testosterone influences the digital growth pat-
tern as indicated by the lower second to fourth digit
length ratio in males than in females [23-25], and that
Caucasian males have higher serum testosterone values and
lower second to fourth digit length ratios than Oriental
males [26,27]. Such testosterone effects on the digital
growth pattern with ethnic difference may explain why
male dominant manifestation was observed in the previ-
ous studies primarily from Caucasian countries and was
not found in this study. Lastly, LBD was more prevalent in
patients with triplications than in those with duplications.
This suggests that LBD primarily occurs when the effects
of BHLHA9 overdosage are considerably elevated.
Genomic basis of the Japanese founder copy number
gains
The duplications/triplications were associated with the
same fusion point and variable haplotype patterns. Since
there was no sequence homology or low-copy repeats
around the breakpoints, it is unlikely that such duplica-
tions/triplications were recurrently produced in different
individuals by non-allelic homologous recombination
(NAHR) [17,20]. Instead, it is assumed that a Japanese
founder duplication took place in a single ancestor, and
was spread with subsequent triplication and modifica-
tion of the haplotype patterns.
The most likely genomic basis of the Japanese duplications/
triplications is illustrated in Additional file 9. Notably, a
4 bp (GACA) microhomology was identified at the dupli-
cation fusion point (Figure 2B). A microhomology refers
to two to five nucleotides common to the sequences
of the two breakpoints, and is found as an overlapping se-
quence at the join point [16,19,20]. This suggests that the
Japanese founder duplication was generated by replication-
based mechanisms such as fork stalling and template
switching (FoSTeS) and microhomology-mediated break-
induced replication (MMBIR), because the presence of
such a microhomology is characteristic of FoSTeS/MMBIR
[17-20]. Indeed, such a simple tandem duplication with a
microhomology can be produced by one time FoSTeS/MMBIR [17-20], although it could also be generated by
non-homologous end-joining (NHEJ) [17]. Since the
[A-14] haplotype was most prevalent on the duplicated/
triplicated segments, it is inferred that a genomic re-
arrangement occurred in an ancestor with the [A-14]
haplotype, yielding the founder duplication with the
[A-14] + [A-14] haplotype. Furthermore, the presence of
multiple stimulants for genomic rearrangements around
the breakpoint on YWHAE intron 1 would have facilitated
the generation of the founder duplication. In particular,
non-B structures are known to stimulate the occurrence
of both replication-based FoSTeS/MMBIR and double-
strand breaks and resultant NHEJ [17,28,29], although the
relative importance of each non-B DNA structure is
largely unknown.
Subsequent triplication and haplotype modification can
develop from the Japanese founder duplication through
unequal interchromatid and interchromosomal recom-
binations [17,20]. Indeed, a tandem triplication with the
[A-14] + [A-14] + [A-14] haplotype can be generated by
unequal exchange between sister chromatids with the
[A-14] + [A-14] haplotype, and various haplotype pat-
terns are yielded by unequal interchromosomal exchanges
involving the duplicated or triplicated segments. Further-
more, the haplotype variation would be facilitated by un-
equal exchanges between sister chromatids harboring
duplications/triplications with various haplotype patterns
and by the further unequal interchromosomal exchanges.
Underlying factors for the phenotypic variability
The duplications/triplications were accompanied by limb
malformations with variable expressivity and incomplete
penetrance. Although this may suggest the presence of a
possible modifier(s) for the development of limb malfor-
mations, such a modifier(s) was not detected. In particu-
lar, while patient-to-carrier transmission of duplications/
triplications was not identified in this study, even patient-
to-carrier-to-patient transmission has been reported in
three pedigrees [5,6,10]. Such transmission pattern with
incomplete penetrance characterized by skipping of a gen-
eration is apparently inexplicable by assuming a modifier
(s) interacting with BHLHA9 or independent of BHLHA9
on the duplication/triplication positive chromosome 17,
on the normal chromosome 17, or on other chromosomes
(Figure 3, Models A, B, and C, see also the legends in
Figure 3).
In this regard, it is noteworthy that the development of
limb malformations is obviously dependent on the size of
genomic segment subjected to copy number gains. Actu-
ally, limb malformation has occurred in only one of 21 large
duplications encompassing BHLHA9 (average 1.55 Mb,
mean 1.12 Mb) and in 29 of 80 small duplications encom-
passing BHLHA9 (average 244 kb, mean 263 kb) (P = 5.9 ×
10−3) [8]. Consistent with this, the patients with large and
Figure 3 Models for a modifier(s) and effects of the duplication size. In models A–C, the yellow bars show chromosome 17, and the light
green bars indicate other chromosomes. The two red dots represent the duplication at 17p13.3, and the blue dots indicate a putative modifier(s).
Black painted diamonds represent limb malformation positive patients, dot-associated and gray painted diamonds indicate clinically normal carriers
with the duplications and the modifier(s) respectively, and white painted diamonds denote clinically normal subjects without both the duplications
and the modifier(s). A. This model assumes that co-existence of the duplication and a cis-acting modifier(s) causes limb malformation. If co-existence
of the duplication and the cis-acting modifier(s) is associated with incomplete penetrance, this can explain all the transmission patterns observed to
date, including the patient-to-carrier transmission and the presence of ≥ 2 affected children. B. This model postulates that the presence of a cis-acting
modifier(s) on the normal chromosome 17 leads to limb malformation by enhancing the expression of the single BHLHA9, together with duplicated
BHLHA9 on the homologous chromosome. C. This model postulates that co-existence of the duplication at 17p13.3 and a modifier(s) on other
chromosome causes limb malformation. In models D–E, the red bars represent BHLHA9, the blue circles indicate a physiological cis-regulatory
element for BHLHA9, and the green circles indicate a non-physiological modifier(s) for BHLHA9. D. The physiological cis-regulatory element may be
duplicated or non-duplicated, depending on its position relative to the size of the duplications. BHLHA9 expression can be higher in small duplications
than large duplications. E. The non-physiological modifier(s) can be transferred to various positions of the duplication positive chromosome 17,
depending on the recombination places (see Model A). BHLHA9 expression can be higher in small duplications than large duplications
irrespective of the position of the modifier(s).
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opmental retardation and limb malformation, respectively
[8]. It is likely that a physiological cis-regulatory element
for BHLHA9 (e.g., an enhancer) can frequently but not in-
variably work on both of the duplicated BHLHA9 when
the duplication size is small but is usually incapable of
working on duplicated BHLHA9 when the duplication size
is large, probably because of the difference in the chroma-
tin structure (see Model D in Figure 3). Similar findings
have also been reported in other genes. For example, small(~150 kb) and relatively small (600–800 kb) duplications
involving a putative testis-specific enhancer(s) for SOX9
have caused 46,XX testicular and ovotesticular disorders
of sex development respectively, whereas large duplica-
tions (~2 Mb) involving the enhancer(s) have permitted
normal ovarian development in 46,XX individuals [30].
Thus, a plausible explanation may be that a range of
limb malformations emerge when the effects of BHLHA9
overdosage exceed the threshold for the development of
SHFM, SHFLD, or GWC, depending on the conditions of
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of duplications/triplications as an important but not
definitive factor. One may argue that this notion is
inconsistent with the apparent anticipation phenomenon
that is suggested by the rare patient-to-carrier transmis-
sion and the frequent carrier-to-patient transmission of
the duplications/triplications, because no specific factor(s)
exaggerating the development of limb malformations is
postulated in the next generation. However, the skewed
transmission pattern would primarily be ascribed to ascer-
tainment bias rather than anticipation [31]. Indeed, while
clinically normal parents of disease positive children
would frequently be examined for the underlying genetic
factor(s) of the children, clinically normal children born to
disease positive parents would not usually be studied for
such factor(s), as exemplified in this study. Similarly, the
frequent patient-to-patient transmission of the duplica-
tions/triplications would also be ascribed to ascertainment
bias, because molecular studies would preferentially be
performed in such families. Nevertheless, the apparently
autosomal dominant inheritance pattern of limb malfor-
mations in several families may still suggest the relevance
of a non-physiological cis-acting modifier(s) (see Models
A and E in Figure 3). It is possible that such a modifier(s),
once transferred onto the duplication/triplication positive
chromosome 17, is usually co-transmitted with the dupli-
cations/triplications, leading to a specific condition in
which the effects of BHLHA9 overdosage frequently but
not invariably exceed the threshold for the development
of limb malformations in offsprings with the duplications/
triplications.
Remarks
Several matters should be pointed out in the present
study. First, in contrast to diverse duplication sizes in
non-Japanese populations [5-9], the size of the genomic
segment subjected to duplications/triplications was iden-
tical in this study. Since families 1–27 were derived from
various places of Japan, there is no selection bias in
terms of a geographic distribution. Rather, since the
small duplications/triplications identified in this study
were not associated with developmental retardation, it is
likely that they spread throughout Japan primarily via
carriers with normal fitness and were found via patients
with limb malformations. Obviously, this notion does
not exclude the possible presence of other types of du-
plications/triplications at 17p13.3 in Japan. Second, ex-
cept for the duplications/triplications at 17p13.3, we
could reveal a homozygous WNT10B mutation (SHFM6)
only in a single SHFM family and chromosome 10q24
duplications (SHFM3) only in three SHFM families.
Thus, underlying factors are still unknown in the
remaining 20 families, although tiny deletions and/or
duplications affecting the known SHFM loci might havebeen overlooked because of the low resolution of the
array. In addition, although all the probands had a nor-
mal karyotype, there might be cryptic translocations
and/or inversions involving the known SHFM loci.
Third, no deletion of BHLHA9 was identified in the 51
probands and in the 200 control subjects. This argues
against the relevance of BHLHA9 haploinsufficiency to
limb malformations, and coincides with the Japanese
founder duplication being produced by a replication-
mediated mechanism rather than an interchromatid/
interchromosomal (but not an intrachromatid) NAHR
that can lead to both deletions and duplications as a mir-
ror image [17]. Furthermore, it remains to be determined
(i) whether gain-of-function mutations (and possibly loss-
of-function mutations as well) of BHLHA9 are identified
in patients with limb malformations, (ii) whether duplica-
tions/triplications involving BHLHA9 underlie limb mal-
formations other than SHFM, SHFLD, and GWC, and (iii)
whether BHLHA9-containing duplications/triplications are
also the most frequent underlying factors for limb malfor-
mations in non-Japanese populations.
Conclusions
The results imply that (i) duplications/triplications in-
volving BHLHA9 at chromosome 17p13.3 constitute a
strong susceptibility factor for the development of a
range of limb malformations including SHFM, SHFLD,
and GWC; (ii) the Japanese founder duplication was
generated by a replication-based mechanism and spread
with subsequent triplication and haplotype modification
through recombination-based mechanisms; and (iii) clin-
ical variability appears to be due to multiple factors in-
cluding the size of duplications/triplications. Thus, the
present study provides useful information on the devel-
opment of limb malformations.Additional files
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